Procept Biorobotics Corp. ((PRCT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The clinical study titled ‘PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs’ aims to evaluate the performance and safety of the AQUABEAM Robotic System. This system is used for the resection and removal of prostate tissue in patients with lower urinary tract symptoms and localized prostate cancer. The study’s significance lies in its potential to offer a minimally invasive treatment option, improving patient outcomes and quality of life.
The intervention being tested is the Aquablation therapy, a device-based treatment known as Robotic Waterjet Treatment. This minimally invasive procedure uses a high-velocity saline waterjet to remove prostate tissue, guided by real-time imaging, offering a heat-free alternative to traditional methods.
The study follows an interventional design with a single-group model, meaning all participants receive the same treatment. There is no masking involved, and the primary purpose is treatment-focused, aiming to assess the therapy’s effectiveness and safety.
The study began on November 22, 2022, with primary completion expected by August 5, 2025. The last update was submitted on this date, indicating ongoing progress and adjustments as the study continues.
This clinical update could positively impact Procept Biorobotics Corp.’s stock performance by showcasing innovation in prostate cancer treatment. Investors might view this as a promising development, potentially increasing interest and confidence in the company’s market position, especially if results show significant improvement over existing therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.